Atorvastatin and prostate cancer - a phase 2 clinical trial

被引:0
|
作者
Murtola, Teemu J.
Riikonen, Jarno
Syvala, Heimo
Tolonen, Teemu
Koskimaki, Juha
Pakarainen, Tomi
Kaipia, Antti
Isotalo, Taina
Kujala, Paula
Tammela, Teuvo
机构
关键词
D O I
10.1158/1538-7445.AM2017-CT133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CT133
引用
收藏
页数:2
相关论文
共 50 条
  • [21] Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial
    Phillips, Ryan
    Shi, William Yue
    Deek, Matthew
    Radwan, Noura
    Lim, Su Jin
    Antonarakis, Emmanuel S.
    Rowe, Steven P.
    Ross, Ashley E.
    Gorin, Michael A.
    Deville, Curtiland
    Greco, Stephen C.
    Wang, Hailun
    Denmeade, Samuel R.
    Paller, Channing J.
    Dipasquale, Shirl
    DeWeese, Theodore L.
    Song, Daniel Y.
    Wang, Hao
    Carducci, Michael A.
    Pienta, Kenneth J.
    Pomper, Martin G.
    Dicker, Adam P.
    Eisenberger, Mario A.
    Alizadeh, Ash A.
    Diehn, Maximilian
    Tran, Phuoc T.
    JAMA ONCOLOGY, 2020, 6 (05) : 650 - 659
  • [22] Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin
    Bybee, Kevin A.
    Lee, John H.
    O'Keefe, James H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (04) : 1217 - 1229
  • [23] Rhodamine-123: Therapy for hormone refractory prostate cancer, a phase I clinical trial
    Jones, LW
    Narayan, KS
    Shapiro, CE
    Sweatman, TW
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (04) : 435 - 440
  • [24] Phase I/II clinical trial of gene therapy for hormone refractory metastatic prostate cancer
    Gotoh, A
    Terao, S
    Shirakawa, T
    JOURNAL OF GENE MEDICINE, 2006, 8 (03): : 371 - 372
  • [25] A phase II clinical trial of sorafenib in androgen-independent prostate cancer: Characterization of pharmacokinetics
    Jain, Lokesh
    Gardner, Erin R.
    Aragon-Ching, Jeanny B.
    Compton, Kathryn
    Venitz, Jurgen
    Wright, John J.
    Dahut, William L.
    Figg, William D.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3576S - 3576S
  • [26] A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies
    Supiot, Stephane
    Shubbar, Shubber
    Fleshner, Neil
    Warde, Padraig
    Hersey, Karen
    Wallace, Kris
    Cole, Heather
    Sweet, Joan
    Tsihlias, John
    Jewett, Michael A. S.
    Klotz, Laurence
    Bristow, Robert G.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 (01) : 53 - 60
  • [27] Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    Dahut, William L.
    Madan, Ravi A.
    Karakunnel, Joyson J.
    Adelberg, David
    Gulley, James L.
    Turkbey, Ismail B.
    Chau, Cindy H.
    Spencer, Shawn D.
    Mulquin, Marcia
    Wright, John
    Parnes, Howard L.
    Steinberg, Seth M.
    Choyke, Peter L.
    Figg, William D.
    BJU INTERNATIONAL, 2013, 111 (08) : 1269 - 1280
  • [28] Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial
    Mincheff, M
    Tchakarov, S
    Zoubak, S
    Loukinov, D
    Botev, C
    Altankova, I
    Georgiev, G
    Petrov, S
    Meryman, HT
    EUROPEAN UROLOGY, 2000, 38 (02) : 208 - 217
  • [29] Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results
    Lubaroff, David M.
    Konety, Badrinath R.
    Link, Brian
    Gerstbrein, Jack
    Madsen, Tammy
    Shannon, Mary
    Howard, Jeanne
    Paisley, Jennifer
    Boeglin, Diana
    Ratliff, Timothy L.
    Williams, Richard D.
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7375 - 7380
  • [30] Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic
    Madsen, Lydia T.
    Kuban, Deborah A.
    Choi, Seungtaek
    Davis, John W.
    Kim, Jeri
    Lee, Andrew K.
    Domain, Debora
    Levy, Larry
    Pisters, Louis L.
    Pettaway, Curtis A.
    Ward, John F.
    Logothetis, Christopher
    Hoffman, Karen E.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (07): : 993 - 998